美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SAB Biotherapeutics, Inc. Warrant

0.0276

0.0000

成交量：- -

成交額：- -

市值：28.73萬

市盈率：-0.01

高：0.0276

開：0.0276

低：0.0276

收：0.0276

52周最高：0.1800

52周最低：0.0205

股本：1,041.11萬

流通股本：1,041.11萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.8053

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

SAB Bio公布SAB-142針對成人自身免疫性1型糖尿病患者的額外一期臨床數據

Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)盤中異動早盤急速跳水9.65%報0.034美元

SAB Bio的SAB-142三期T1d治療臨床試驗首例患者已用藥

SAB Bio宣佈SAB-142在3期T1d治療中的1期研究確認性臨床結果積極

Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價拉升20.16% 市值漲18.33萬美元

Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)盤中異動急速跳水13.35%

Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)盤中異動早盤股價大跌19.28%報0.027美元

Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價重挫22.01% 市值跌19.68萬美元

Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價重挫11.43% 市值跌10.76萬美元

Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價拉升14.00% 市值漲12.43萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SABSW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SABSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SABSW\",,,,,undefined,":{"symbol":"SABSW","market":"US","secType":"STK","nameCN":"SAB Biotherapeutics, Inc. Warrant","latestPrice":0.0276,"timestamp":1774036800000,"preClose":0.0276,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":10411067,"shares":10411067,"eps":-2.8053,"marketStatus":"休市中","change":0,"latestTime":"03-20 16:00:00 EDT","open":0.0276,"high":0.0276,"low":0.0276,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.8053,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0276,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SABSW\",,,,,undefined,":{"symbol":"SABSW","floatShares":10411067,"roa":"--","roe":"--","lyrEps":0,"shares":10411067,"dividePrice":0,"high":0.0276,"amplitude":0,"preClose":0.0276,"low":0.0276,"week52Low":0.0205,"pbRate":"--","week52High":0.18,"institutionHeld":0,"latestPrice":0.0276,"eps":-2.8053,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.8053,"open":0.0276,"prevYearClose":0.0312,"prevWeekClose":0.0366,"prevMonthClose":0.0299,"prevQuarterClose":0.0312,"fiveDayClose":0.0366,"twentyDayClose":0.0341,"sixtyDayClose":0.025},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SABSW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-08-10","symbol":"SABSW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1660104000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-03-29","symbol":"SABSW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1648526400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SABSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SABSW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SABSW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131758194","title":"SAB Bio公布SAB-142針對成人自身免疫性1型糖尿病患者的額外一期臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1131758194","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131758194?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 19:31","pubTimestamp":1773142280,"startTime":"0","endTime":"0","summary":"SAB Bio（SAB Biotherapeutics, Inc.）近日发布了其候选药物SAB-142在已确诊患有自身免疫性1型糖尿病的成年患者中开展的一期临床试验的进一步数据。此次数据更新为该药物的临床开发提供了更多支持信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SABS","SABSW","BK4139"],"gpt_icon":0},{"id":"2612173289","title":"Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)盤中異動 早盤急速跳水9.65%報0.034美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612173289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612173289?lang=zh_tw&edition=fundamental","pubTime":"2026-02-19 22:44","pubTimestamp":1771512246,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日22时44分，Sab Biotherapeutics Inc C/Wts 22/10/2026 股票出现异动，股价大幅跳水9.65%。Sab Biotherapeutics Inc C/Wts 22/10/2026 股票所在的生物技术行业中，整体跌幅为1.01%。Sab Biotherapeutics Inc C/Wts 22/10/2026 公司简介：SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602192244069541785d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602192244069541785d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SABSW"],"gpt_icon":0},{"id":"1193156416","title":"SAB Bio的SAB-142三期T1d治療臨床試驗首例患者已用藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1193156416","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193156416?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 21:04","pubTimestamp":1766063048,"startTime":"0","endTime":"0","summary":"SAB Bio的SAB-142三期T1d治疗临床试验首例患者已用药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SABSW","BK4139","SABS"],"gpt_icon":0},{"id":"1162504708","title":"SAB Bio宣佈SAB-142在3期T1d治療中的1期研究確認性臨床結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1162504708","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162504708?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976504,"startTime":"0","endTime":"0","summary":"SAB Bio宣布SAB-142在3期T1d治疗中的1期研究确认性临床结果积极","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SABS","SABSW"],"gpt_icon":0},{"id":"2584907900","title":"Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價拉升20.16% 市值漲18.33萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584907900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584907900?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 00:10","pubTimestamp":1763568603,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日00时10分，Sab Biotherapeutics Inc C/Wts 22/10/2026 股票出现异动，股价快速上涨20.16%。Sab Biotherapeutics Inc C/Wts 22/10/2026 股票所在的生物技术行业中，整体跌幅为0.90%。Sab Biotherapeutics Inc C/Wts 22/10/2026 公司简介：SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120001003a704c13b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120001003a704c13b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SABSW"],"gpt_icon":0},{"id":"2584953285","title":"Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)盤中異動 急速跳水13.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584953285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584953285?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 04:32","pubTimestamp":1763411521,"startTime":"0","endTime":"0","summary":"北京时间2025年11月18日04时32分，Sab Biotherapeutics Inc C/Wts 22/10/2026 股票出现异动，股价急速下跌13.35%。Sab Biotherapeutics Inc C/Wts 22/10/2026 股票所在的生物技术行业中，整体涨幅为1.22%。Sab Biotherapeutics Inc C/Wts 22/10/2026 公司简介：SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118043202a4a862fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118043202a4a862fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SABSW"],"gpt_icon":0},{"id":"2583634623","title":"Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)盤中異動 早盤股價大跌19.28%報0.027美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583634623","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583634623?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 23:48","pubTimestamp":1763135281,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日23时48分，Sab Biotherapeutics Inc C/Wts 22/10/2026 股票出现波动，股价大幅下挫19.28%。Sab Biotherapeutics Inc C/Wts 22/10/2026 股票所在的生物技术行业中，整体涨幅为0.62%。Sab Biotherapeutics Inc C/Wts 22/10/2026 公司简介：SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114234801a4a1f9ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114234801a4a1f9ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SABSW"],"gpt_icon":0},{"id":"2581449570","title":"Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價重挫22.01% 市值跌19.68萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581449570","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581449570?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 22:31","pubTimestamp":1762439499,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时31分，Sab Biotherapeutics Inc C/Wts 22/10/2026 股票出现波动，股价快速下挫22.01%。Sab Biotherapeutics Inc C/Wts 22/10/2026 股票所在的生物技术行业中，整体跌幅为0.17%。Sab Biotherapeutics Inc C/Wts 22/10/2026 公司简介：SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223139a48dad37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223139a48dad37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SABSW"],"gpt_icon":0},{"id":"2575933213","title":"Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價重挫11.43% 市值跌10.76萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575933213","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575933213?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 23:58","pubTimestamp":1760371081,"startTime":"0","endTime":"0","summary":"北京时间2025年10月13日23时58分，Sab Biotherapeutics Inc C/Wts 22/10/2026 股票出现异动，股价快速下跌11.43%。Sab Biotherapeutics Inc C/Wts 22/10/2026 股票所在的生物技术行业中，整体涨幅为0.52%。Sab Biotherapeutics Inc C/Wts 22/10/2026 公司简介：SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013235801a45df464&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013235801a45df464&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SABSW"],"gpt_icon":0},{"id":"2572937248","title":"Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com)股價拉升14.00% 市值漲12.43萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572937248","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572937248?lang=zh_tw&edition=fundamental","pubTime":"2025-10-01 01:00","pubTimestamp":1759251601,"startTime":"0","endTime":"0","summary":"北京时间2025年10月01日01时00分，Sab Biotherapeutics Inc C/Wts 22/10/2026 股票出现异动，股价急速拉升14.00%。Sab Biotherapeutics Inc C/Wts 22/10/2026 股票所在的生物技术行业中，整体涨幅为0.20%。Sab Biotherapeutics Inc C/Wts 22/10/2026 公司简介：SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001010001a6a8cd6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001010001a6a8cd6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SABSW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}